Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Type 2 myocardial infarction occurs due to a mismatch ...

Researchers found that those with both type 2 diabetes and chronic obstructive pulmonary disease (COPD) had lower all-cause and respiratory-cause mortality survival probabilities than those without ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial. The results of the BOREAS ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...